Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (greater than or equal to 16 to 80 Years Old) With Partial Onset Seizures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2023
Price :
$35
*
At a glance
- Drugs Brivaracetam (Primary)
- Indications Partial epilepsies; Seizures
- Focus Registrational; Therapeutic Use
- Acronyms BRITE
- Sponsors UCB; UCB Biosciences; UCB Pharma Inc
- 01 Jan 2023 Results of post hoc analysis evaluating long-term retention, reasons for discontinuation, efficacy, tolerability, and health-related quality of life (HRQOL) during adjunctive brivaracetam (BRV) treatment in adults with focal seizures by number of lifetime antiseizure medications published in the Epilepsy and Behavior
- 17 May 2022 Results of pooled post hoc (N01252/NCT00490035, N01253/NCT00464269, and N01358/NCT01261325 studies) analysis published in the Epilepsia
- 26 Apr 2022 Results of post hoc analysis of 3 phase III trials (N01252 [NCT00490035], N01253 [NCT00464269], N01358 [NCT01261325]) assessing the time-course of treatment-emergent adverse events (TEAEs) potentially associated with behavioral disorders (BAEs) in adults with focal seizures during adjunctive brivaracetam (BRV) treatment presented at the 74th Annual Meeting of the American Academy of Neurology 2022